Global Heparin Market

Global Heparin Market Size, Trends & Analysis - Forecasts to 2026 By Type (Low Molecular Weight and Ultra-Low Molecule Weight), By Route of Administration (Intravenous and Subcutaneous), By Application Form (Venous Thromboembolism, Atrial Fibrillation, Renal Impairment, Coronary Artery Disease, and Others), By End-Use (Inpatients and Outpatients), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); Competitive Landscape, Company Market Share Analysis, and Competitor Analysis

Category Healthcare

Format

This report was recently updated on November 16 2024 with the latest and most recent market numbers

Heparin Market Insights

Heparin is an antiplatelet drug that is developed naturally by basophils and mast cells in all mammals. It's being used to manage cardiac problems and dysfunctional angina by acting as an anticoagulant or blood thinner and preventing the development of blood clots within blood vessels.

The market drivers which contribute to the growth in the heparin market include the increasing incidence of medical treatments like deep vein thrombosis (DVT) and pulmonary embolism (PE), expanding cardiac disorders, rising federal funding for upgrading health services, and comprehensive research and development (R&D) activities, the surging incidence of chronic diseases, and the developing aging population.

The global heparin market is anticipated to expand due to an increase in the incidence of venous thrombosis as a consequence of multiple factors involved like cardiovascular diseases. Furthermore, the use of heparin in a variety of operations, such as orthopedic and cardiac surgeries, as well as a spike in the proportion of people treated with such procedures, are driving the market forward. The use of kidney dialysis is the trigger due to an increase in chronic kidney disease around the world. The rise in demand for heparin is due to an increase in the number of injuries and medical surgeries.

In addition, pharmaceutical and biotechnology organizations are launching novel drugs to improve heparin's therapeutic ability while reducing its adverse reactions. The development of synthetic and semi-synthetic heparin mimetics that aid in the treatment of cancers, coagulation, and inflammatory diseases is driving up product demand. Various developments in the field of carbohydrate syntheses, such as building block planning, linking reactions, and the emergence of sequential strategies, are also driving the market. Significant medical research activities to produce ultra-low molecular weight heparin for use in leukemia are also boosting the market's prospects.

The effectiveness of these medications as an anticoagulant is expected to be one of the main drivers augmenting global demand development. Moreover, several forces, including technological advances and novel product releases, are foreseen to drive the global market's expansion. The expanded use of these medications has accelerated progress in the production of LMWH. Furthermore, technical advances have resulted in the emergence of newer types, including the ULMWH. As a result, these trends are predicted to have a favourable effect on demand throughout the forecast period.

global heparin market

Heparin Market: By Type

Based on the type, the market is classified as low molecular weight and ultra-low molecule weight. Owing to the product's relatively consistent antiplatelet effect, the low molecular weight segment is likely to report the largest heparin market share during the forecast period. Low molecular weight (LMWH) anticoagulants aid in avoiding blood clots, treat venous thromboembolism, and treat myocardial infarction. They're often used to manage thrombosis. Furthermore, because of its quick onset of operation, easy laboratory surveillance is feasible, which will help the segment expand even faster. Due to the corporatization of drugs with enhanced therapeutic impact, ultra-low molecular weight heparin is foreseen to witness the fastest-growing segment throughout the forecast period.

Heparin Market: By Route Of Administration

Based on the route of administration, the market is categorized as intravenous, and subcutaneous. Because of the lower costs correlated with hospitalization, the subcutaneous segment is expected to lead the market. Moreover, from the viewpoint of the patient, the subcutaneous route is favored due to the convenience of management, increasing demand for home care, and shorter time of medication. Besides that, the advantages of this path of administration comprise a lower probability of systemic illness and an increased standard of living.

Heparin Market: By Application Form

Based on the application form, the market is segmented into venous thromboembolism, atrial fibrillation, renal impairment, coronary artery disease, and others. Owing to the growing intensity and occurrence of heart-related diseases, coronary artery disease is presumed to be the market leader. As per the American Heart Association, almost 92.1 million American individuals suffered from a certain variant of cardiovascular disease in 2018. Furthermore cardiovascular disease accounts for about one-third of all mortality in the United States, contributing to about 2,300 deaths every day, thus, aiding to the dominance of this segment.

Heparin Market: By End-Use

Depending on end-use, the market is categorized as inpatients and outpatients. The outpatient segment is likely to predominate in this market. The growing inclination of patients for the subcutaneous route of administration is a primary factor driving market development. Furthermore, outpatient care costs are lower than inpatient hospital costs. Also, outpatient treatment was linked with a reduced risk of chronic venous thromboembolism, according to several reports reported in the NCBI, thus, leading to the dominance of the outpatient segment in this market.

asia pacific heparin market

Heparin Market: By Region

As per the geographical analysis, the market can be classified into North America (the US, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa and Central & South America. Because of the rise in sporting injuries and cardiovascular diseases, North America is expected to dominate the global industry in terms of sales. Moreover, the region's major proportion can be due to higher healthcare spending rates, increasing patient recognition, and advanced healthcare facilities. The Asia Pacific is presumed to rise at the highest CAGR throughout the forecast period. Constantly expanding healthcare facilities, the existence of undiscovered markets, industrial prosperity, and increasing efforts by private & public organizations are amongst the factors contributing to the region's explosive development.

Heparin Market Share and Competitor Analysis

GlaxoSmithKline plc, Pfizer, Inc., Baxter, Leo Pharma A/S, Sanofi, Dr. Reddy’s Laboratories Ltd., Aspen Holdings, B. Braun Medical Inc., Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., Opocrin S.p.A., Bioiberica S.A.U., Fresenius SE & Co. KGaA, Hebei Changshan Biochemical Pharmaceutical Co., Ltd., are the top players in the heparin market.

Please note: This is not an exhaustive list of companies profiled in the report.

Chapter 1 Methodology

1.1 Market Scope & Definitions

1.2 Estimates & Forecast Calculation

1.3 Historical Data Overview And Validation

1.4 Data Types

1.4.1 Secondary

1.4.2 Primary

Chapter 2 Report Outlook

2.1 Heparin Market Overview, 2019-2026

2.1.1 Industry Overview

2.1.2 Type Overview

2.1.3 Route Of Administration Overview

2.1.4 End-Use Overview

2.1.5 Application Overview

2.1.6 Regional Overview

Chapter 3 Heparin Market Trends

3.1 Market Segmentation

3.2 Industry Background, 2019-2026

3.3 Market Key Trends

3.3.1 Positive Trends

3.3.1.1 Increasing prevalence of chronic diseases

3.3.1.2 Growing demand for whole blood and blood components transfusion

3.3.1.3 Increasing geriatric population

3.3.2 Restraints

3.3.2.1 Risk of blood transmitted diseases & increasing blood substitutes

3.4 Prospective Growth Scenario

3.4.1 Type Growth Scenario

3.4.2 Route Of Administration Growth Scenario

3.4.3 End-Use Growth Scenario

3.4.4 Application Growth Scenario

3.5 COVID-19 Influence over Industry Growth

3.7 Porter’s Analysis

3.7 PESTEL Analysis

3.8 Value Chain & Supply Chain Analysis

3.9 Regulatory Framework

3.9.1 North America

3.9.2 Europe

3.9.3 APAC

3.9.4 LATAM

3.9.5 MEA

3.10 Technology Overview

3.11 Market Share Analysis, 2020

3.11.1 Company Positioning Overview, 2020

Chapter 4 Heparin Market, By Type

4.1 Type Outlook

4.2 Low Molecular Weight

4.2.1 Market Size, By Region, 2019-2026 (USD Million)

4.3 Ultra-Low Molecule Weight

4.3.1 Market Size, By Region, 2019-2026 (USD Million)

Chapter 5 Heparin Market, By Route Of Administration

5.1 Route Of Administration Outlook

5.2 Intravenous

5.2.1 Market Size, By Region, 2019-2026 (USD Million)

5.3 Subcutaneous

5.3.1 Market Size, By Region, 2019-2026 (USD Million)

Chapter 6 Heparin Market, By End-Use

6.1 End-Use Outlook

6.2 Inpatients

6.2.1 Market Size, By Region, 2019-2026 (USD Million)

6.3 Outpatients

6.3.1 Market Size, By Region, 2019-2026 (USD Million)

Chapter 7 Heparin Market, By Application

7.1 Application Outlook

7.2 Venous Thromboembolism

7.2.1 Market Size, By Region, 2019-2026 (USD Million)

7.3 Atrial Fibrillation

7.3.1 Market Size, By Region, 2019-2026 (USD Million)

7.4 Renal Impairment

7.4.1 Market Size, By Region, 2019-2026 (USD Million)

7.5 Coronary Artery Disease

7.5.1 Market Size, By Region, 2019-2026 (USD Million)

Chapter 8 Heparin Market, By Region

8.1 Regional outlook

8.2 North America

8.2.1 Market Size, By Country 2019-2026 (USD Million)

8.2.2 Market Size, By Type, 2019-2026 (USD Million)

8.2.3 Market Size, By Route Of Administration, 2019-2026 (USD Million)

8.2.4 Market Size, By End-Use, 2019-2026 (USD Million)

8.2.5 Market Size, By Application, 2019-2026 (USD Million)

8.2.6 U.S.

8.2.6.1 Market Size, By Type, 2019-2026 (USD Million)

8.2.6.2 Market Size, By Route Of Administration, 2019-2026 (USD Million)

8.2.6.3 Market Size, By End-Use, 2019-2026 (USD Million)

8.2.6.4 Market Size, By Application, 2019-2026 (USD Million)

8.2.7 Canada

8.2.7.1 Market Size, By Type, 2019-2026 (USD Million)

8.2.7.2 Market Size, By Route Of Administration, 2019-2026 (USD Million)

8.2.7.3 Market Size, By End-Use, 2019-2026 (USD Million)

8.2.7.4 Market Size, By Application, 2019-2026 (USD Million)

8.3 Europe

8.3.1 Market Size, By Country 2019-2026 (USD Million)

8.3.2 Market Size, By Type, 2019-2026 (USD Million)

8.3.3 Market Size, By Route Of Administration, 2019-2026 (USD Million)

8.3.4 Market Size, By End-Use, 2019-2026 (USD Million)

8.3.5 Market Size, By Application, 2019-2026 (USD Million)

8.3.6 Germany

8.3.6.1 Market Size, By Type, 2019-2026 (USD Million)

8.3.6.2 Market Size, By Route Of Administration, 2019-2026 (USD Million)

8.3.6.3 Market Size, By End-Use, 2019-2026 (USD Million)

8.3.6.4 Market Size, By Application, 2019-2026 (USD Million)

8.3.7 UK

8.3.7.1 Market Size, By Type, 2019-2026 (USD Million)

8.3.7.2 Market Size, By Route Of Administration, 2019-2026 (USD Million)

8.3.7.3 Market Size, By End-Use, 2019-2026 (USD Million)

8.3.7.4 Market Size, By Application, 2019-2026 (USD Million)

8.3.8 France

8.3.8.1 Market Size, By Type, 2019-2026 (USD Million)

8.3.8.2 Market Size, By Route Of Administration, 2019-2026 (USD Million)

8.3.8.3 Market Size, By End-Use, 2019-2026 (USD Million)

8.3.8.4 Market Size, By Application, 2019-2026 (USD Million)

8.3.9 Italy

8.3.9.1 Market Size, By Type, 2019-2026 (USD Million)

8.3.9.2 Market Size, By Route Of Administration, 2019-2026 (USD Million)

8.3.9.3 Market Size, By End-Use, 2019-2026 (USD Million)

8.3.9.4 Market Size, By Application, 2019-2026 (USD Million)

8.3.10 Spain

8.3.10.1 Market Size, By Type, 2019-2026 (USD Million)

8.3.10.2 Market Size, By Route Of Administration, 2019-2026 (USD Million)

8.3.10.3 Market Size, By End-Use, 2019-2026 (USD Million)

8.3.10.4 Market Size, By Application, 2019-2026 (USD Million)

8.3.11 Russia

8.3.11.1 Market Size, By Type, 2019-2026 (USD Million)

8.3.11.2 Market Size, By Route Of Administration, 2019-2026(USD Million)

8.3.11.3 Market Size, By End-Use, 2019-2026 (USD Million)

8.3.11.4 Market Size, By Application, 2019-2026 (USD Million)

8.4 Asia Pacific

8.4.1 Market Size, By Country 2019-2026 (USD Million)

8.4.2 Market Size, By Type, 2019-2026 (USD Million)

8.4.3 Market Size, By Route Of Administration, 2019-2026 (USD Million)

8.4.4 Market Size, By End-Use, 2019-2026 (USD Million)

8.4.5 Market Size, By Application, 2019-2026 (USD Million)

8.4.6 China

8.4.6.1 Market Size, By Type, 2019-2026 (USD Million)

8.4.6.2 Market Size, By Route Of Administration, 2019-2026 (USD Million)

8.4.6.3 Market Size, By End-Use, 2019-2026 (USD Million)

8.4.6.4 Market Size, By Application, 2019-2026 (USD Million)

8.4.7 India

8.4.7.1 Market Size, By Type, 2019-2026 (USD Million)

8.4.7.2 Market Size, By Route Of Administration, 2019-2026 (USD Million)

8.4.7.3 Market Size, By End-Use, 2019-2026 (USD Million)

8.4.7.4 Market Size, By Application, 2019-2026 (USD Million)

8.4.8 Japan

8.4.8.1 Market Size, By Type, 2019-2026 (USD Million)

8.4.8.2 Market Size, By Route Of Administration, 2019-2026 (USD Million)

8.4.8.3 Market Size, By End-Use, 2019-2026 (USD Million)

8.4.8.4 Market Size, By Application, 2019-2026 (USD Million)

8.4.9 Australia

8.4.9.1 Market Size, By Type, 2019-2026 (USD Million)

8.4.9.2 Market size, By Route Of Administration, 2019-2026 (USD Million)

8.4.9.3 Market Size, By End-Use, 2019-2026 (USD Million)

8.4.9.4 Market Size, By Application, 2019-2026 (USD Million)

8.4.10 South Korea

8.4.10.1 Market Size, By Type, 2019-2026 (USD Million)

8.4.10.2 Market Size, By Route Of Administration, 2019-2026 (USD Million)

8.4.10.3 Market Size, By End-Use, 2019-2026 (USD Million)

8.4.10.4 Market Size, By Application, 2019-2026 (USD Million)

8.5 Latin America

8.5.1 Market Size, By Country 2019-2026 (USD Million)

8.5.2 Market Size, By Type, 2019-2026 (USD Million)

8.5.3 Market Size, By Route Of Administration, 2019-2026 (USD Million)

8.5.4 Market Size, By End-Use, 2019-2026 (USD Million)

8.5.5 Market Size, By Application, 2019-2026 (USD Million)

8.5.6 Brazil

8.5.6.1 Market Size, By Type, 2019-2026 (USD Million)

8.5.6.2 Market Size, By Route Of Administration, 2019-2026 (USD Million)

8.5.6.3 Market Size, By End-Use, 2019-2026 (USD Million)

8.5.6.4 Market Size, By Application, 2019-2026 (USD Million)

8.5.7 Mexico

8.5.7.1 Market Size, By Type, 2019-2026 (USD Million)

8.5.7.2 Market Size, By Route Of Administration, 2019-2026 (USD Million)

8.5.7.3 Market Size, By End-Use, 2019-2026 (USD Million)

8.5.7.4 Market Size, By Application, 2019-2026 (USD Million)

8.5.8 Argentina

8.5.8.1 Market Size, By Type, 2019-2026 (USD Million)

8.5.8.2 Market Size, By Route Of Administration, 2019-2026 (USD Million)

8.5.8.3 Market Size, By End-Use, 2019-2026 (USD Million)

8.5.8.4 Market Size, By Application, 2019-2026 (USD Million)

8.6 MEA

8.6.1 Market Size, By Country 2019-2026 (USD Million)

8.6.2 Market Size, By Type, 2019-2026 (USD Million)

8.6.3 Market Size, By Route Of Administration, 2019-2026 (USD Million)

8.6.4 Market Size, By End-Use, 2019-2026 (USD Million)

8.6.5 Market Size, By Application, 2019-2026 (USD Million)

8.6.6 Saudi Arabia

8.6.6.1 Market Size, By Type, 2019-2026 (USD Million)

8.6.6.2 Market Size, By Route Of Administration, 2019-2026 (USD Million)

8.6.6.3 Market Size, By End-Use, 2019-2026 (USD Million)

8.6.6.4 Market Size, By Application, 2019-2026 (USD Million)

8.6.7 UAE

8.6.7.1 Market Size, By Type, 2019-2026 (USD Million)

8.6.7.2 Market Size, By Route Of Administration, 2019-2026 (USD Million)

8.6.7.3 Market Size, By End-Use, 2019-2026 (USD Million)

8.6.7.4 Market Size, By Application, 2019-2026 (USD Million)

8.6.8 South Africa

8.6.8.1 Market Size, By Type, 2019-2026 (USD Million)

8.6.8.2 Market Size, By Route Of Administration, 2019-2026 (USD Million)

8.6.8.3 Market Size, By End-Use, 2019-2026 (USD Million)

8.6.8.4 Market Size, By Application, 2019-2026 (USD Million)

Chapter 9 Company Landscape

9.1 Competitive Analysis, 2020

9.2 GlaxoSmithKline Plc

9.2.1 Company Overview

9.2.2 Financial Analysis

9.2.3 Strategic Positioning

9.2.4 Info Graphic Analysis

9.3 Pfizer, Inc

9.3.1 Company Overview

9.3.2 Financial Analysis

9.3.3 Strategic Positioning

9.3.4 Info Graphic Analysis

9.4 Baxter

9.4.1 Company Overview

9.4.2 Financial Analysis

9.4.3 Strategic Positioning

9.4.4 Info Graphic Analysis

9.5 Leo Pharma A/S

9.5.1 Company Overview

9.5.2 Financial Analysis

9.5.3 Strategic Positioning

9.5.4 Info Graphic Analysis

9.6 Sanofi

9.6.1 Company Overview

9.6.2 Financial Analysis

9.6.3 Strategic Positioning

9.6.4 Info Graphic Analysis

9.7 Dr Reddy’s Laboratories Ltd.

9.7.1 Company Overview

9.7.2 Financial Analysis

9.7.3 Strategic Positioning

9.7.4 Info Graphic Analysis

9.8 Aspen Holdings

9.8.1 Company Overview

9.8.2 Financial Analysis

9.8.3 Strategic Positioning

9.8.4 Info Graphic Analysis

9.9 B. Braun Medical Inc.

9.9.1 Company Overview

9.9.2 Financial Analysis

9.9.3 Strategic Positioning

9.9.4 Info Graphic Analysis

9.10 Fresenius SE & Co. KGaA

9.10.1 Company Overview

9.10.2 Financial Analysis

9.10.3 Strategic Positioning

9.10.4 Info Graphic Analysis

9.11 Teva Pharmaceutical Industries Ltd.

9.11.1 Company Overview

9.11.2 Financial Analysis

9.11.3 Strategic Positioning

9.11.4 Info Graphic Analysis

9.12 Opocrin S.p.A.

9.12.1 Company Overview

9.12.2 Financial Analysis

9.12.3 Strategic Positioning

9.12.4 Info Graphic Analysis

9.13 Bioiberica S.A.U.

9.13.1 Company Overview

9.13.2 Financial Analysis

9.13.3 Strategic Positioning

9.13.4 Info Graphic Analysis

9.14 Fresenius SE & Co. KGaA

9.14.1 Company Overview

9.14.2 Financial Analysis

9.14.3 Strategic Positioning

9.14.4 Info Graphic Analysis

9.15 Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

9.15.1 Company Overview

9.15.2 Financial Analysis

9.15.3 Strategic Positioning

9.15.4 Info Graphic Analysis

9.16 Other Companies

9.16.1 Company Overview

9.16.2 Financial Analysis

9.16.3 Strategic Positioning

9.16.4 Info Graphic Analysis

The Global Heparin Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Heparin Market.

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe. Privacy

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

What is the projected market size of the global heparin market?

The global heparin market size is projected to grow CAGR value of 6.5% between 2021 to 2026.

Who are the major vendors in the heparin market?

Key and innovative vendors in the heparin market include GlaxoSmithKline plc, Pfizer, Inc., Baxter, Leo Pharma A/S, Sanofi, Dr. Reddy’s Laboratories Ltd., Aspen Holdings, B. Braun Medical Inc., Fresenius SE & Co. KGaA, and Teva Pharmaceutical Industries Ltd., among others.

Which region has the highest market share in the heparin market?

The North American region is estimated to hold the largest share of the heparin market.

What is the Covid-19 impact on future heparin manufacturers?

The COVID-19 pandemic has increased demand for various therapeutic drugs and the development of new drugs is expected to have a positive impact on the growth of the heparin market.

What are the major drivers in the heparin market?

The growing investment in drug discovery, increasing number of patients suffering from cardiac issues, expanding pharmaceutical manufacturing capabilities, and the growing geriatric population are the major drivers of the heparin market.